Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

Phase 1/2 Completed 52 enrolled Longboard Pharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.

Timeline

Start: 2022-03-03
Primary completion: 2023-11-16
Completion: 2023-11-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	bexicaserin	Small molecule	—	Oral

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

Summary

Timeline

Drugs

Indications